Form 4 · Filed Feb 17, 2026, 12:00 PM UTC
ELVN/Enliven Therapeutics, Inc.
Heyman Richard A. — director
AI Thesis
A thesis has not been generated for this filing yet — usually available within 60 seconds of EDGAR publication. Refresh shortly.
Research signal, not investment advice. Form 4 AI surfaces SEC filings and applies an analytical layer — it does not predict prices or recommend trades. Past performance does not guarantee future results. See methodology and public track record for how scores are computed.
Transactions
1 row| Date | Code | Direction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Feb 12, 2026 | A | other | 19,234 | $0 | — | 19,234 |
Source: SEC EDGAR raw filing ↗ · Accession 0001584759-26-000008